In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
Thanks to our deeper understanding of the underlying biology and molecular mechanisms that govern cancer, we are gaining important ground in tackling the myriad mediators of this disease.
People think cancer care is unaffordable because of the high prices of cancer medicines. Some state that innovations in oncology mostly happen thanks to massive investments in the private sector.
A survey reveals that physicians outside the field of oncology are insufficiently updated on the latest advances in cancer care, thus increasing the risk of providing misleading information and inadequate support to patients.
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.
Available data now allows evidence-based treatment of cancer diagnosed during pregnancy and new therapies are improving many young patients’ survival prospects, but couples’ preferences and values must continue to guide medical teams even when hope is scarce
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.